| Filed On | Filing |
|---|---|
| 16 Oct 2024 |
8-K/A: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. |
| 23 Feb 2023 |
8-K/A: Results of Operations and Financial Condition
Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023 |
| 22 Sep 2022 |
8-K/A: Submission of Matters to a Vote of Security Holders
As previously reported in the Original Form 8-K, the Company’s stockholders cast a majority of votes in favor of recommending a frequency of one year for future executive compensation advisory votes, through an advisory, non-binding reso... |
| 21 Jan 2022 |
8-K/A: Financial Statements and Exhibits
(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. |
Loading...